Are you Dr. Ewenstein?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
15 Claflin Path
Brookline, MA 02445Phone+1 617-731-9211
Summary
- Dr. Bruce Ewenstein, MD is an oncologist in Brookline, Massachusetts. He is currently licensed to practice medicine in Massachusetts.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1983 - 1986
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1980 - 1983
Albert Einstein College of MedicineClass of 1980
Certifications & Licensure
MA State Medical License 1984 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- ADVATE Post Authorization Safety Surveillance Start of enrollment: 2004 Oct 14
- Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2014 Sep 30
- A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2017 Oct 13
- Join now to see all
Publications & Presentations
PubMed
- 82 citationsNephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia BBruce M. Ewenstein, Clifford M. Takemoto, Indira Warrier, Jeanne M. Lusher, P. Saidi
Blood. 1997-02-01 - 95 citationsBAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expressionBarbara A. Konkle, Christopher E. Walsh, Miguel A. Escobar, Neil C. Josephson, Guy Young
Blood. 2021-02-11 - 38 citationsRecombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.Peter Turecek, Rachel C Peck, Savita Rangarajan, Christopher Reilly-Stitt, Michael Laffan
Thrombosis Research. 2021-02-18
Press Mentions
Results of a Randomized Phase III/IV Trial Comparing Intermittent Bolus Versus Continuous Infusion of Antihaemophilic Factor (Recombinant) in Adults with Severe or Moderately Severe Haemophilia A Undergoing Major Orthopaedic SurgeryMarch 27th, 2021
Shire to Present New Data at Isth 2017 to Advance the Standard of Care in HemophiliaJune 23rd, 2017
Shire to Present New Data at Isth 2017 to Advance the Standard of Care in HemophiliaJune 23rd, 2017- Join now to see all
